Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1258026

The risk factors for bleeding events in patients taking rivaroxaban – possible role of pharmacogenetics


Slišković, Ana Marija; Šimičević, Livija; Vrkić Kirhmajer, Majda; Ganoci, Lana; Holik, Hrvoje; Samardžić, Jure; Božina, Tamara
The risk factors for bleeding events in patients taking rivaroxaban – possible role of pharmacogenetics // 20th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2022)
Prag, Češka Republika, 2022. (poster, međunarodna recenzija, neobjavljeni rad, znanstveni)


CROSBI ID: 1258026 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
The risk factors for bleeding events in patients taking rivaroxaban – possible role of pharmacogenetics

Autori
Slišković, Ana Marija ; Šimičević, Livija ; Vrkić Kirhmajer, Majda ; Ganoci, Lana ; Holik, Hrvoje ; Samardžić, Jure ; Božina, Tamara

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, neobjavljeni rad, znanstveni

Skup
20th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2022)

Mjesto i datum
Prag, Češka Republika, 18.09.2022. - 21.09.2022

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
drug safety ; interactions ; multidisciplinary ; pharmacogenetic ; risk factors ; rivaroxaban ; rivaroxaban-related bleeding

Sažetak
Background: Rivaroxaban has large interindividual trough concentration variability effecting its efficacy and safety. It is a substrate of ABCB1, ABCG2, CYP2J2, CYP3A4, transporters and enzymes responsible for its transport or metabolism. This variability could be associated to protein-coding genes polymorphisms, drug-drug interactions, age, liver and kidney function. Aim: Evaluate possible risk factors (genes polymorphisms, drug-drug interactions, age, liver and kidney function) for rivaroxaban-associated bleeding adverse reactions. Patients and Methods: Presented patients, with rivaroxaban-associated bleeding, are part of a large case-controlled study population (funded by the Croatian Science Foundation: Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction). Data on bleeding, concomitant medications, liver and kidney function, and red blood cell count was collected. Pharmacogenetic analysis was performed on 7500 Real-Time PCR System (Applied Biosystems, USA) using specific TaqMan® DME Assay and TaqMan® SNP Assay reagents (Applied Biosystems, USA) for genotyping of relevant pharmacogenes: CYP3A4*1B, *22, CYP3A5*3, CYP2J2*7, ABCB1 (c.1236C>T, c.3435C>T), and ABCG2 (c.421C>A). Results: Thirteen patients (median age 74 years, range 61-80) with rivaroxaban-associated bleeding were analysed: gastrointestinal (N = 7), epistaxis (N = 4), haematuria (N = 1) and gynaecological bleeding (N = 1). In 8/13 drug-drug interactions with increased bleeding risk were found. Two patients had eGFR > 90, while five patients had eGFR < 60. One patient was CYP3A4*22 homozygote, two were CYP2J2*7 heterozygous, two patients had ABCB1 T/T genotype, and three ABCG2 C/A genotype. Three patients who experienced bleeding did not have investigated risk factors. Conclusion: Our results indicate the need for more detailed medical examination prior to rivaroxaban treatment, with emphasis on renal function, particularly in the elderly, with more attention paid to concomitant therapy (possible drug-drug interactions). Due to the small number of patients no pharmacogenetic conclusion might be stated, but findings indicate the need of further research.

Izvorni jezik
Engleski

Znanstvena područja
Interdisciplinarne prirodne znanosti, Kliničke medicinske znanosti, Farmacija, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)



POVEZANOST RADA


Projekti:
HRZZ-UIP-2020-02-8189 - Uloga farmakogenomike u predviđanju nuspojava kardiovaskularnih lijekova (PGx-CardioDrug) (Božina, Tamara, HRZZ - 2020-02) ( CroRIS)

Ustanove:
Medicinski fakultet, Zagreb,
Opća bolnica "Dr. Josip Benčević",
Klinički bolnički centar Zagreb


Citiraj ovu publikaciju:

Slišković, Ana Marija; Šimičević, Livija; Vrkić Kirhmajer, Majda; Ganoci, Lana; Holik, Hrvoje; Samardžić, Jure; Božina, Tamara
The risk factors for bleeding events in patients taking rivaroxaban – possible role of pharmacogenetics // 20th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2022)
Prag, Češka Republika, 2022. (poster, međunarodna recenzija, neobjavljeni rad, znanstveni)
Slišković, A., Šimičević, L., Vrkić Kirhmajer, M., Ganoci, L., Holik, H., Samardžić, J. & Božina, T. (2022) The risk factors for bleeding events in patients taking rivaroxaban – possible role of pharmacogenetics. U: 20th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2022).
@article{article, author = {Sli\v{s}kovi\'{c}, Ana Marija and \v{S}imi\v{c}evi\'{c}, Livija and Vrki\'{c} Kirhmajer, Majda and Ganoci, Lana and Holik, Hrvoje and Samard\v{z}i\'{c}, Jure and Bo\v{z}ina, Tamara}, year = {2022}, keywords = {drug safety, interactions, multidisciplinary, pharmacogenetic, risk factors, rivaroxaban, rivaroxaban-related bleeding}, title = {The risk factors for bleeding events in patients taking rivaroxaban – possible role of pharmacogenetics}, keyword = {drug safety, interactions, multidisciplinary, pharmacogenetic, risk factors, rivaroxaban, rivaroxaban-related bleeding}, publisherplace = {Prag, \v{C}e\v{s}ka Republika} }
@article{article, author = {Sli\v{s}kovi\'{c}, Ana Marija and \v{S}imi\v{c}evi\'{c}, Livija and Vrki\'{c} Kirhmajer, Majda and Ganoci, Lana and Holik, Hrvoje and Samard\v{z}i\'{c}, Jure and Bo\v{z}ina, Tamara}, year = {2022}, keywords = {drug safety, interactions, multidisciplinary, pharmacogenetic, risk factors, rivaroxaban, rivaroxaban-related bleeding}, title = {The risk factors for bleeding events in patients taking rivaroxaban – possible role of pharmacogenetics}, keyword = {drug safety, interactions, multidisciplinary, pharmacogenetic, risk factors, rivaroxaban, rivaroxaban-related bleeding}, publisherplace = {Prag, \v{C}e\v{s}ka Republika} }




Contrast
Increase Font
Decrease Font
Dyslexic Font